R. Navari

Publications176
h-index40
Citations6,115
Highly Influential Citations232
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Aapro
  • 692 Publications, 24,164 Citations
  • P. Hesketh
  • 198 Publications, 12,716 Citations
  • R. Gralla
  • 401 Publications, 16,914 Citations
  • L. Schwartzberg
  • 485 Publications, 11,048 Citations
  • Publications
  • Influence
Responses of cerebral arteries and arterioles to acute hypotension and hypertension.
The responses of cerebral precapillary vessels to changes in arterial blood pressure were studied in anesthetized cats equipped with cranial windows for the direct observation of the pial… Expand
  • 721
  • 31
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
BACKGROUND We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy. METHODS In a randomized, double-blind, phase 3… Expand
  • 185
  • 20
  • PDF
Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
BACKGROUND The purpose of the study was to compare the effectiveness of olanzapine (OLN) and aprepitant (APR) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients… Expand
  • 219
  • 17
  • PDF
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
PurposeOlanzapine has been shown to be a safe and effective agent for the prevention of chemotherapy-induced nausea and vomiting (CINV). Olanzapine may also be an effective rescue medication for… Expand
  • 141
  • 11
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
The objective of this study was to compare the efficacy and toxicity of the liposome‐encapsulated doxorubicin, TLC D‐99 (Myocet, Elan Pharmaceuticals, Princeton, NJ), and conventional doxorubicin in… Expand
  • 424
  • 10
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
BACKGROUND The localization of substance P in brain-stem regions associated with vomiting, and the results of studies in ferrets, led us to postulate that a neurokinin-1-receptor antagonist would be… Expand
  • 351
  • 9
Antimicrobial use in patients with advanced cancer receiving hospice care.
Patients with advanced cancer receiving hospice and palliative care are highly susceptible to infections. The decision whether to treat an active or suspected infection in end-of-life care may be… Expand
  • 76
  • 9
Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles and… Expand
  • 65
  • 7
Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy
Background Studies have shown that there is a high prevalence of depression in cancer patients. Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or… Expand
  • 55
  • 6
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two…
BACKGROUND Highly emetogenic chemotherapy induces emesis in almost all patients in the absence of prophylaxis. Guidelines recommend use of a neurokinin-1 (NK-1) receptor antagonist in conjunction… Expand
  • 108
  • 5